References
- Higashiyama M, Hokari R, Kurihara C, Ueda T, Watanabe C, Tomita K, Indomethacin-induced small intestinal injury is ameliorated by cilostazol, a specific PDE-3 inhibitor. Scand J Gastroenterol 2012;8-9:993–1002.
- Lee YJ, Eun JR. Cilostazol decreases ethanol-mediated TNFalpha expression in RAW264.7 murine macrophage and in liver from binge drinking mice. Korean J Physiol Pharmacol 2012;16:131–8.
- Fujita K, Nozaki Y, Wada K, Yoneda M, Endo H, Takahashi H, Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. Gut 2008;57:1583–91.
- Ikeda Y, Matsumata T, Takenaka K, Yamagata M, Sugimachi K. Effects of doxorubicin and/or cilostazol on cancer cells during liver regeneration after two-thirds hepatectomy in rats. Oncology 1998;55:354–6.
- Suzuki K, Aiura K, Ueda M, Kitajima M. The influence of platelets on the promotion of invasion by tumor cells and inhibition by antiplatelet agents. Pancreas 2004;29:132–40.
- Ohba R, Otaka M, Odashima M, Jin M, Komatsu K, Konishi N, Effect of cilostazol, a selective type-III phosphodiesterase inhibitor, on water-immersion stress-induced gastric mucosal injury in rats. J Gastroenterol 2006;41:34–40.
- Iba T, Kidokoro A, Fukunaga M, Takuhiro K, Ouchi M, Ito Y. Comparison of the protective effects of type III phosphodiesterase (PDE3) inhibitor (cilostazol) and acetylsalicylic acid on intestinal microcirculation after ischemia reperfusion injury in mice. Shock 2006;26:522–6.
- Matsunaga H, Hokari R, Higashiyama M, Kurihara C, Okada Y, Watanabe C, Cilostazol, a specific PDE-3 inhibitor, ameliorates chronic ileitis via suppression of interaction of platelets with monocytes. Am J Physiol Gastrointest Liver Physiol 2009;297:G1077–84.
- Morris DS, Porterfield JR, Sawyer MD. Hemorrhagic cholecystitis in an elderly patient taking aspirin and cilostazol. Case Rep Gastroenterol 2008;2:203–7.